A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures

• Published in: Neuropsychopharmacology (New York, N.Y.) Vol. 43; no. 8; pp. 1772 - 1778
• Main Authors: Politte, Laura C., Scahill, Lawrence, Figueroa, Janet, McCracken, James T., King, Bryan, McDougle, Christopher J.
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.07.2018; Springer International Publishing
• Subjects: Adolescent; Analysis of covariance; Anxiety; Attention Deficit Disorder with Hyperactivity - drug therapy; Attention deficit hyperactivity disorder; Autism; Autism Spectrum Disorder - drug therapy; Autistic children; Child; Child, Preschool; Children; Delayed-Action Preparations; Female; Guanfacine - administration & dosage; Humans; Male; Obsessive compulsive disorder; Problem Behavior; Psychotropic Drugs - administration & dosage; Sleep; Sleep - drug effects; Stereotyped Behavior - drug effects; Treatment Outcome
• ISSN: 0893-133X; 1740-634X; 1740-634X
• DOI: 10.1038/s41386-018-0039-3

In a prior report, we showed that extended-release guanfacine (GEXR) is safe and effective for children with autism spectrum disorder (ASD) accompanied by ADHD symptoms. Here, we examine the impact of GEXR on oppositional behavior, anxiety, repetitive behavior, and sleep disturbance. Sixty-two subjects with ASD (53 boys, 9 girls; ages 5-14 years) were randomly assigned to GEXR (n = 30) or placebo (n = 32) for 8 weeks. Outcomes include the Home Situation Questionnaire-Modified for ASD (HSQ-ASD), Anxiety scale of the Child and Adolescent Symptom Inventory (CASI), Children's Yale-Brown Obsessive-Compulsive Scale-Modified for ASD (CYBOCS-ASD), and Children's Sleep Habits Questionnaire (CSHQ). A repeated measures linear mixed model was used to determine the effects of treatment group and time on HSQ scores. For other measures, change from baseline was evaluated with Analysis of Covariance (ANCOVA).After 8 weeks of treatment, parent ratings of oppositional behavior on the HSQ declined by 44% (per item mean from 3.4 to 1.9) in the GEXR group compared to 12% (from 3.3 to 2.9) for placebo (p = 0.004). Repetitive behavior on the CYBOCS-ASD showed a significantly greater decline in GEXR-treated participants compared to placebo (24% vs. <1%, p = 0.01). No group differences were observed on CASI Anxiety or CSHQ (p = 0.64 and 0.75, respectively). GEXR was effective in reducing oppositional behavior and, more modestly, repetitive behavior. GEXR was not superior to placebo for anxiety, though baseline anxiety ratings were low. GEXR did not significantly improve sleep habits. Future studies could focus on repetitive behavior or anxiety, symptoms with limited treatment options.